Review highlights therapeutic potential and mechanisms of action of indole hybrids in drug-resistant cancers, indicating new strategies for treatment.
Drug‐resistant cancer is a major obstacle to effective treatment, causing poor clinical outcomes, financial pressure, and healthcare burdens, highlighting the urgent need for new chemotherapeutics. Indole derivatives are valuable anticancer scaffolds with multitargeted effects. Indole hybrids, in particular, exert multitargeted actions that address drug resistance mechanisms, offering unique advantages for overcoming resistant cancers. The present manuscript aims to summarize the current landscape of indole hybrids, with therapeutic potential against drug‐resistant cancers, covering literature published since 2021. Additionally, the structure–activity relationships and mechanisms of action are addressed to inform the further rational design of novel candidates.
No takes yet. Share an insight, caveat, or question.
Li et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: